索利那新联合坦索罗辛治疗Ⅲ型前列腺炎的临床研究  

Clinical effectiveness and safety of combined therapy with solifenacin and tamsulosin for patients with type Ⅲ prostatitis

作　　者：郭建华[1] 龚旻[1] 胡巍[1] 顾建军[1] 陈楚红[1] 祝凤明[1] 伊庆同[1] 王华[1] 陈长青[1] 

机构地区：[1]上海市浦东医院复旦大学附属浦东医院泌尿外科,201399

出　　处：《中华泌尿外科杂志》2013年第11期839-842,共4页Chinese Journal of Urology

基　　金：上海市浦东新区卫生系统优秀青年医学人才培养计划（PWRq2011-12）

摘　　要：目的 探讨索利那新联合坦索罗辛治疗Ⅲ型前列腺炎的临床效果. 方法 2010年5月至2011年9月,应用前瞻性随机开放平行对照研究将160例Ⅲ型前列腺炎患者平均分为观察组和对照组,观察组给予坦索罗辛（0.2 mg,每晚1次）＋索利那新（5 mg,每天1次）,对照组给予坦索罗辛（0.2 mg,每晚1次）治疗,共12周,治疗前后均记录慢性前列腺炎症状指数（NIH-CPSI）评分、膀胱过度活动症症状评分（OABSS）及前列腺液白细胞数目. 结果 观察组与对照组治疗前NIH-CPSI评分、OABSS评分及前列腺液白细胞数目等基线资料比较差异均无统计学意义（P＞0.05）.观察组治疗前后NIH-CPSI评分为32.29±5.58和16.03±4.41,OABSS评分为9.56±1.91和5.03± 1.16,前列腺液白细胞数目为（9.75±2.24）和（9.08±2.26）个/HP,治疗前后比较差异均有统计学意义（P＜0.01）.对 照组治疗前后NIH-CPSI评分为32.31±5.61和24.28±4.75,差异有统计学意义（P＜0.01）,治疗前后OABSS评分（9.46±1.89和9.28±2.20）及前列腺液白细胞数目[（9.71±2.14）和（9.12±1.99）个/HP]比较差异无统计学意义（P＞0.05）.观察组与对照组治疗后NIH-CPSI、OABSS比较差异有统计学意义（P＜0.01）,而前列腺液白细胞计数比较差异无统计学意义（P＞0.05）.观察组2例出现短期轻度头晕,对照组1例轻度头晕,均未予处理；观察组2例有轻度口干,疗程结束口干消失. 结论 索利那新联合坦索罗辛治疗Ⅲ型前列腺炎疗效优于单用坦索罗辛,可显著改善Ⅲ型前列腺炎患者的膀胱过度活动症症状.Objective To evaluate the efficacy and safety of the combined therapy of tamsulosin and solifenacin for type III prostatitis patients. Methods From May 2010 to September 2011, 160 patients diagnosed as type III prostatitis were included in this prospective study. All the 160 patients were randomly divided into 2 groups： combined therapy group （n = 80） in which patients were treated with tamsulosin 0.2 mg once daily and solifenacin 5 mg once daily for 12 weeks, and tamsulosin group （n= 80） in which pa- tients were treated with tamsulosin 0.2 mg once daily for 12 weeks. NIH chronic prostatitis symptom index （NIH-CPSI） , overactive bladder symptom score （OABSS） and white blood cell （WBC） counts in expressed prostate secretion （EPS） were evaluated before and after treatment. Results At baseline there was no sig- nificant difference between the 2 groups. The NIH-CPSI （32.29±5.58 versus 16,03±4.41 ） , OABSS （9.56± 1.91 versus 5.03± 1.16） and EPS WBC count （9.75±2.24 versus 9.08±2.26） significantly decreased in the combined therapy group after 12 weeks treatment （P〈0.01）. The NIH-CPSI （32.31±5.61 versus 24.28± 4.75 ） （P〈0.01） also significantly decreased in tamsulosin group after 12 weeks treatment. There was no significant decrease for OABSS （9.46±1.89 versus 1.99） in tamsulosin group after treatment （P〉0 9.28±2.20） and EPS WBC count （9.71±2.14 versus 9.12± 05）. The NIH-CPSI and OABSS in combination group after treatment were significantly lower than those in tamsulosin group （P〈 0.01 ）. Conclusion Combined therapy with solifenacin and tamsulosin can improve the symptoms for patients with type III prostatitis better than tamsulosin monotherapy.

关 键 词：前列腺炎 索利那新 肾上腺素能Α拮抗剂 药物疗法 联合 前瞻性研究 

分 类 号：R697.33[医药卫生—泌尿科学]